Daewoong Pharmaceuticals

daewoong.com

Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both the domestic and international markets. Through our strong M&S divisions, Daewoong has the largest prescription drug sales in the South Korean market. Presently, we commercialize 10 blockbuster products. In addition, we have built a strong internal core competency for new drug development and have expanded regional and global collaborations with international partners. To reach our goal to become a global health care company, Daewoong has expanded international operations establishing branches offices throughout Asia and research centers in the US, China, and India. Currently, Daewoong is constructing a new manufacturing facility under cGMP guidelines to meet the needs of our global partners.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

PFIZER AND BIONTECH ANNOUNCE A PARTNERSHIP WITH BIOVAC TO DEVELOP AND DISTRIBUTE COVID-19 VACCINE DOSES IN AFRICA

Pfizer | July 22, 2021

news image

Pfizer Inc. and BioNTech SE today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, also known as "Biovac," a South African biopharmaceutical business headquartered in Cape Town, to produce the Pfizer-BioNTech COVID-19 Vaccine for sale inside the African Union. Biovac will manufacture and distribute COVID-19 vaccines as part of Pfizer and BioNTech's worldwide COVID-19 vaccine supply chain and production network, which currently spans th...

Read More

Pharma Tech

ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF IND FOR PROSTHETIC JOINT INFECTIONS

Armata Pharmaceuticals, Inc | August 02, 2022

news image

Armata Pharmaceuticals, Inc. a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration has cleared Armata's Investigational New Drug application for AP-SA02 in prosthetic joint infection. The company is initiating start-up activities for the Phase 1b/2a trial that will explore the safety, tolerability, and pharmacokinetics of intravenous and i...

Read More

Business Insights

SIMULATIONS PLUS COLLABORATES WITH MULTINATIONAL PHARMACEUTICAL COMPANY TO PROVIDE MODELING & SIMULATION SUPPORT FOR COVID-19 TREATMENT

Simulations Plus, Inc | June 24, 2022

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound. Early in the COVID-19 pandemic, the pharma...

Read More

Pharmacy Market

KROMATID ANNOUNCES LAUNCH OF KROMATID PINPOINT FISH TP53/CEP17 KIT FOR SYNTHETIC OLIGONUCLEOTIDE-BASED FISH ASSAY

KromaTiD Inc | January 14, 2022

news image

KromaTiD is excited to announce early access to our KromaTiD Pinpoint FISH TP53/CEP17 Kit, our new product designed to supply the highest resolution, lowest background, and lowest limit of detection available. KromaTiD's Pinpoint FISH™ Kit, allows for better hybridization conditions and eliminating strand degradation steps. Pinpoint FISH™ allows researchers to expand beyond the capabilities of conventional FISH probes to detect smaller targets and design ultra-high...

Read More
news image

Pharmacy Market

PFIZER AND BIONTECH ANNOUNCE A PARTNERSHIP WITH BIOVAC TO DEVELOP AND DISTRIBUTE COVID-19 VACCINE DOSES IN AFRICA

Pfizer | July 22, 2021

Pfizer Inc. and BioNTech SE today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, also known as "Biovac," a South African biopharmaceutical business headquartered in Cape Town, to produce the Pfizer-BioNTech COVID-19 Vaccine for sale inside the African Union. Biovac will manufacture and distribute COVID-19 vaccines as part of Pfizer and BioNTech's worldwide COVID-19 vaccine supply chain and production network, which currently spans th...

Read More
news image

Pharma Tech

ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF IND FOR PROSTHETIC JOINT INFECTIONS

Armata Pharmaceuticals, Inc | August 02, 2022

Armata Pharmaceuticals, Inc. a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration has cleared Armata's Investigational New Drug application for AP-SA02 in prosthetic joint infection. The company is initiating start-up activities for the Phase 1b/2a trial that will explore the safety, tolerability, and pharmacokinetics of intravenous and i...

Read More
news image

Business Insights

SIMULATIONS PLUS COLLABORATES WITH MULTINATIONAL PHARMACEUTICAL COMPANY TO PROVIDE MODELING & SIMULATION SUPPORT FOR COVID-19 TREATMENT

Simulations Plus, Inc | June 24, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound. Early in the COVID-19 pandemic, the pharma...

Read More
news image

Pharmacy Market

KROMATID ANNOUNCES LAUNCH OF KROMATID PINPOINT FISH TP53/CEP17 KIT FOR SYNTHETIC OLIGONUCLEOTIDE-BASED FISH ASSAY

KromaTiD Inc | January 14, 2022

KromaTiD is excited to announce early access to our KromaTiD Pinpoint FISH TP53/CEP17 Kit, our new product designed to supply the highest resolution, lowest background, and lowest limit of detection available. KromaTiD's Pinpoint FISH™ Kit, allows for better hybridization conditions and eliminating strand degradation steps. Pinpoint FISH™ allows researchers to expand beyond the capabilities of conventional FISH probes to detect smaller targets and design ultra-high...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us